journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/30017428/corrigendum-to-validation-of-the-8th-tnm-classification-for-small-cell-lung-cancer-in-a-retrospective-material-from-sweden-lung-cancer-120-june-2018-75-81
#1
Salomon Tendler, Vitali Grozman, Rolf Lewensohn, Georgios Tsakonas, Kristina Viktorsson, Luigi De Petris
No abstract text is available yet for this article.
July 13, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30017426/response-to-low-level-evidence-supporting-the-choice-of-optimal-multimodality-treatment-approach-in-patients-with-stage-iiia-nsclc-ain-t-no-mountain-high-enough%C3%A2-to-keep-me-getting-to-you-by-jeremic-branislav
#2
LETTER
F Couñago, N Rodriguez de Dios, S Montemuiño, J Jové-Teixidó, M Martin, P Calvo-Crespo, M López-Mata, M P Samper-Ots, J L López-Guerra, T García-Cañibano, V Díaz-Díaz, L de Ingunza-Barón, M Murcia-Mejía, P Alcántara, J Corona, M M Puertas, M Chust, M L Couselo, E Del Cerro, J Moradiellos, S Amor, A Varela, I J Thuissard, D Sanz-Rosa, B Taboada
No abstract text is available yet for this article.
July 13, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30017427/at-last-we-can-go-ahead-with-low-dose-ct-screening-for-lung-cancer-in-europe
#3
LETTER
Giulia Veronesi, Javier J Zulueta, Patrick Maisonneuve, Claudia Henschke
No abstract text is available yet for this article.
July 10, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29921448/low-level-evidence-supporting-the-choice-of-optimal-multimodality-treatment-approach-in-patients-with-stage-iiia-nsclc-ain-t-no-mountain-high-enough%C3%A2-to-keep-me-getting-to-you
#4
LETTER
Branislav Jeremic, Antonio Gomez-Caamano, Pavol Dubinsky, Nikola Cihoric, Ivan Igrutinovic, Gregory Videtic
No abstract text is available yet for this article.
June 16, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29914770/nivolumab-induced-pneumonitis-complicated-by-cyst-formation
#5
LETTER
Luis Gorospe, Ana María Ayala-Carbonero, María Eugenia Olmedo-García, Ana Gómez-Rueda, Magda Palka, Laura Mezquita, Pilar Garrido-López
No abstract text is available yet for this article.
June 11, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29961557/economic-burden-of-resected-stage-ib-iiia-non-small-cell-lung-cancer-in-france-germany-and-the-united-kingdom-a-retrospective-observational-study-lucabis
#6
Stefan Andreas, Christos Chouaid, Sarah Danson, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Mark Price, Sorrel Wolowacz, James A Kaye, Ilias Kontoudis
OBJECTIVES: New adjuvant treatments are being developed for patients with resected non-small cell lung cancer (NSCLC). Due to scarcity of real-world data available for treatment costs and resource utilization, health technology and cost-effectiveness assessments can be limited. We estimated the burden and cost-of-illness associated with completely resected stage IB-IIIA NSCLC in France, Germany and the United Kingdom (UK). MATERIALS AND METHODS: Eligible patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC between August 2009 and July 2012...
June 9, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29807862/second-line-therapy-and-advanced-non-small-cell-lung-cancer-what-about-smoking
#7
LETTER
Alain Braillon
No abstract text is available yet for this article.
May 21, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858033/prognostic-impact-of-the-integration-of-volumetric-quantification-of-the-solid-part-of-the-tumor-on-3dct-and-fdg-pet-imaging-in-clinical-stage-ia-adenocarcinoma-of-the-lung
#8
Hideyuki Furumoto, Yoshihisa Shimada, Kentaro Imai, Sachio Maehara, Junichi Maeda, Masaru Hagiwara, Tetsuya Okano, Ryuhei Masuno, Masatoshi Kakihana, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda
OBJECTIVES: The aim of this study was to conduct comparative analyses of the biological malignant potential of clinical stage IA adenocarcinoma using positron emission tomography/computed tomography (PET/CT), high-resolution CT (HRCT), and three-dimensional CT (3DCT). The predictive performance of these parameters was evaluated in terms of clinical outcomes and pathological invasiveness (positive lymphatic permeation, blood-vessel invasion, pleural invasion, and lymph-node metastasis)...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858032/functional-cooperation-between-hif-1%C3%AE-and-c-jun-in-mediating-primary-and-acquired-resistance-to-gefitinib-in-nsclc-cells-with-activating-mutation-of-egfr
#9
Shuyan Meng, Guorui Wang, Yang Lu, Zhen Fan
OBJECTIVE: Hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP-1) are important transcription factors regulating expression of genes involved in cell survival. HIF-1α and c-Jun are key components of HIF-1 and AP-1, respectively, and are regulated by epidermal growth factor receptor (EGFR)-mediated cell signaling and tumor microenvironmental cues. The roles of HIF-1α and c-Jun in development of resistance to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) with activating mutation of EGFR have not been explored...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858031/association-of-molecular-status-and-metastatic-organs-at-diagnosis-in-patients-with-stage-iv-non-squamous-non-small-cell-lung-cancer
#10
C C H J Kuijpers, L E L Hendriks, J L Derks, A-M C Dingemans, A S R van Lindert, M M van den Heuvel, R A Damhuis, S M Willems
OBJECTIVES: Biological predisposition for specific metastatic organs might differ between molecular subgroups of lung cancer. We aimed to assess the association between molecular status and metastatic organs at diagnosis in a nationwide stage IV non-squamous non-small cell lung cancer ((ns)-NSCLC) cohort. METHODS: All ns-NSCLC from 2013 that were stage IV at diagnosis were identified from the Netherlands Cancer Registry, which records information on metastatic organs at diagnosis...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858030/effect-of-mutant-variants-of-the-kras-gene-on-pd-l1-expression-and-on-the-immune-microenvironment-and-association-with-clinical-outcome-in-lung-adenocarcinoma-patients
#11
Alexander T Falk, Nathalie Yazbeck, Nicolas Guibert, Emmanuel Chamorey, Agnès Paquet, Lydia Ribeyre, Coraline Bence, Katia Zahaf, Sylvie Leroy, Charles-Hugo Marquette, Charlotte Cohen, Baharia Mograbi, Julien Mazières, Véronique Hofman, Patrick Brest, Paul Hofman, Marius Ilié
OBJECTIVES: The effect of anti-PD-1/PD-L1 inhibitors on lung adenocarcinomas (LADCs) with KRAS mutations is debatable. We examined the association between specific mutant KRAS proteins and the immune infiltrates with the outcome of patients with LADCs. PATIENTS AND METHODS: In 219 LADCs harboring either wild-type (WT) or mutated KRAS gene, we quantified the density of several immune markers by immunohistochemistry followed by automated digital image analysis. Data were correlated to clinicopathological parameters and outcome of patients...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858029/cost-effectiveness-of-low-dose-ct-screening-for-lung-cancer-in-a-european-country-with-high-prevalence-of-smoking-a-modelling-study
#12
Yuki Tomonaga, Kevin Ten Haaf, Thomas Frauenfelder, Malcolm Kohler, Roger D Kouyos, Mohaned Shilaih, Matthias Lorez, Harry J de Koning, Matthias Schwenkglenks, Milo A Puhan
OBJECTIVES: In Europe, there is uncertainty about the potential effects and cost-effectiveness of low dose computed tomography screening for lung cancer and about the applicability of results of North American studies. We aimed to estimate the effects and cost-effectiveness of lung cancer screening in a population-based setting in Switzerland where the smoking prevalence is high. MATERIALS AND METHODS: The MIcrosimulation Screening ANalysis-Lung (MISCAN) model was adapted using country specific input parameters regarding lung cancer epidemiology, smoking behaviours, and treatment costs...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858028/comparison-of-genetic-profiles-among-primary-lung-tumor-metastatic-lymph-nodes-and-circulating-tumor-dna-in-treatment-na%C3%A3-ve-advanced-non-squamous-non-small-cell-lung-cancer-patients
#13
Fangfang Xie, Yujun Zhang, Xiaowei Mao, Xiaoxuan Zheng, Han Han-Zhang, Junyi Ye, Ruiying Zhao, Xueyan Zhang, Jiayuan Sun
OBJECTIVES: Genetic profiles of primary and metastatic lung tumor have been investigated by previous studies. However, whether they can be replaced by each other to guide treatment remains controversial. Moreover, it is unclear that whether genetic profiles of plasma can reflect genetic divergence between primary and metastatic lesions. MATERIALS AND METHODS: In this prospective study, we collected 35 pairs of matched primary tumor tissue, metastatic lymph nodes and plasma from treatment-naïve patients with advanced non-squamous non-small cell lung cancer (NSCLC) and applied to capture-based sequencing using a panel consisting 56 NSCLC-related genes to interrogate the heterogeneity and similarity among the 3 sites...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858027/osimertinib-compared-docetaxel-bevacizumab-as-third-line-treatment-in-egfr-t790m-mutated-non-small-cell-lung-cancer
#14
Keke Nie, Zhongfa Zhang, Chunling Zhang, Chuanxin Geng, Ling Zhang, Xiajuan Xu, Shichao Liu, Songping Wang, Xingjun Zhuang, Ketao Lan, Youxin Ji
OBJECTIVE: To compare the efficacy and toxicity of osimertinib versus docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated NSCLC. METHODS: In this phase 3, open-label, three-center study, we randomly assigned (1:1) previously treated with TKI-chemotherapy or chemotherapy-TKI recurrent or metastatic advanced non-squamous lung cancer patients into two groups. These patients had acquired EGFR T790M resistance mutation confirmed by tumor tissues or serum...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858026/ild-nsclc-gap-index-scoring-and-staging-system-for-patients-with-non-small-cell-lung-cancer-and-interstitial-lung-disease
#15
Haruki Kobayashi, Tateaki Naito, Katsuhiro Omae, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Masahiro Endo, Toshiaki Takahashi
BACKGROUND AND OBJECTIVE: Patients with advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are commonly excluded from most clinical trials because of acute exacerbation (AE) of ILD triggered by chemotherapy. Data on the efficacy and feasibility of chemotherapy are limited in this patient population. Recently, the ILD-GAP index and staging system was reported as a clinical prognostic factor associated with mortality in patients with ILD. Therefore, we evaluated the incidence of ILD-AE during the surveillance term in this study and the prognosis in patients with NSCLC and ILD using a modified ILD-GAP (ILD-NSCLC-GAP) index scoring system...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858025/alterations-of-notch-pathway-in-patients-with-adenoid-cystic-carcinoma-of-the-trachea-and-its-impact-on-survival
#16
Mian Xie, Shenhai Wei, Xiaojun Wu, Xiaoxiang Li, You You, Chaosheng He
INTRODUCTION: Adenoid cystic carcinoma (ACC) of the trachea lacks of well-characterized molecular markers. There is currently no specific treatment for metastatic ACC of the trachea. This study aimed to identify genomic mutations of Notch pathway and investigate the efficacy of NOTCH inhibitor in ACC of the trachea. METHODS: 73 Patients with ACC of the trachea at four institutions from 2008 to 2016 were identified. Analysis of hotspot mutations in cancer-related genes of Notch pathway was performed using next generation sequencing...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858024/analysis-of-central-nervous-system-efficacy-in-the-j-alex-study-of-alectinib-versus-crizotinib-in-alk-positive-non-small-cell-lung-cancer
#17
Makoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Tomohiro Tanaka, Hiroshi Kuriki, Ali Zeaiter, Tomohide Tamura
OBJECTIVES: We determined the central nervous system (CNS) efficacy of alectinib by calculating time to CNS progression and cumulative incidence rates (CIRs) of CNS progression, non-CNS progression and death in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) enrolled in the J-ALEX phase III study. MATERIALS AND METHODS: Japanese patients aged ≥20 years with ALK-positive NSCLC who were ALK inhibitor-naïve and chemotherapy-naïve, or who had received one previous chemotherapy regimen, were enrolled...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858023/chemoradiotherapy-induced-hemoglobin-nadir-values-and-survival-in-patients-with-stage-iii-non-small-cell-lung-cancer
#18
Erkan Topkan, Ugur Selek, Yurday Ozdemir, Berna A Yildirim, Ozan C Guler, Huseyin Mertsoylu, Stephen M Hahn
PURPOSE: We investigated the influence of change in hemoglobin (Hgb) levels during concurrent chemoradiotherapy (C-CRT) on outcomes of non-anemic patients with stage IIIA/B non-small cell lung cancer (NSCLC). METHODS: We identified 722 patients with stage IIIA/B NSCLC without anemia at baseline [hemoglobin (Hgb) <12 g/dL for women or <13 g/dL for men], either nonsmokers or ex-smokers, who received C-CRT between 2007 and 2012. All patients had received 1-3 cycles of platinum-based doublet chemotherapy during radiotherapy to 60-66 Gy and had documented Hgb measurements before treatment and at weekly intervals for 6 weeks during the C-CRT...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858022/impact-of-a-comprehensive-geriatric-assessment-to-manage-elderly-patients-with-locally-advanced-non-small-cell-lung-cancers-an-open-phase-ii-study-using-concurrent-cisplatin-oral-vinorelbine-and-radiotherapy-gfpc-08-06
#19
Chrystèle Locher, Nicolas Pourel, Hervé Le Caer, Henri Berard, Jean-Bernard Auliac, Isabelle Monnet, Renaud Descourt, Alain Vergnenègre, Isabelle Martel Lafay, Laurent Greillier, Christos Chouaïd
INTRODUCTION: Few data have been published on the optimal management of elderly patients with locally advanced non-small-cell lung cancers (La-NSCLC). This prospective, multicenter, phase II study was undertaken to evaluate the ability of a comprehensive geriatric assessment (CGA) to select the elderly La-NSCLC patients who potentially may benefit from concurrent radio-chemotherapy. METHODS: The main inclusion criteria were: La-NSCLC, >70 years old, at least one measurable target, ECOG performance status (PS) 0/1 and normal CGA...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29858021/characterization-of-tim-3-expression-and-its-prognostic-value-in-patients-with-surgically-resected-lung-adenocarcinoma
#20
Hang Su, Huikang Xie, Chenyang Dai, Yijiu Ren, Yunlang She, Long Xu, Donglai Chen, Dong Xie, Liping Zhang, Gening Jiang, Chang Chen
OBJECTIVES: T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a promising checkpoint. However, its features and prognostic value in lung adenocarcinoma remain undetermined. In this study, we aimed to characterize TIM-3 expression and its prognostic significance in patients with surgically resected lung adenocarcinoma. MATERIALS AND METHODS: Expression of TIM-3 and programmed cell death 1 (PD-1), and density of CD8+ tumor infiltrating lymphocytes (TILs) were evaluated by immunohistochemistry in resected lung adenocarcinoma...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"